BRAF and cancer: We also compared RMC-7977 activity in cancer cells harbouring various activating mutations in the RAS pathway, specifically oncogenic variants of KRAS, NRAS, EGFR or BRAF. RAS-dependent (KRAS, NRAS or EGFR-mutated) cancer cells treated with RMC-7977 exhibited concentration-dependent inhibition of downstream signalling and proliferation in the low nanomolar range (Fig. 2f,g).